MX2020009478A - Compuestos y sus usos para tratar tumores en un paciente. - Google Patents
Compuestos y sus usos para tratar tumores en un paciente.Info
- Publication number
- MX2020009478A MX2020009478A MX2020009478A MX2020009478A MX2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- icd
- subject
- treat tumors
- relates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000037449 immunogenic cell death Effects 0.000 abstract 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con compuestos que pueden usarse para inducir la muerte celular inmunogénica (ICD). En algunos casos, dos o más compuestos se combinan para inducir la ICD. La invención también se relaciona con la combinación de los compuestos que inducen la ICD con un agente que estimula el sistema inmunológico, tal como un inhibidor del punto de control inmunológico, en particular, para tratar cánceres o inhibir el crecimiento tumoral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161849 | 2018-03-14 | ||
| PCT/EP2019/056287 WO2019175243A1 (en) | 2018-03-14 | 2019-03-13 | Compounds and uses thereof to treat tumors in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009478A true MX2020009478A (es) | 2020-10-22 |
Family
ID=61655700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009478A MX2020009478A (es) | 2018-03-14 | 2019-03-13 | Compuestos y sus usos para tratar tumores en un paciente. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210353614A1 (es) |
| EP (1) | EP3765019A1 (es) |
| JP (1) | JP2021517145A (es) |
| KR (1) | KR20200131270A (es) |
| CN (1) | CN111867589A (es) |
| AU (1) | AU2019233596A1 (es) |
| CA (1) | CA3093499A1 (es) |
| IL (1) | IL277158A (es) |
| MX (1) | MX2020009478A (es) |
| RU (1) | RU2020133020A (es) |
| WO (1) | WO2019175243A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4213803A1 (en) * | 2020-09-18 | 2023-07-26 | Merck Patent GmbH | Pharmaceutical preparation |
| JP2025529512A (ja) * | 2022-09-16 | 2025-09-04 | ▲應▼世生物科技（南京）有限公司 | Ｆａｋ阻害剤及びトポイソメラーゼ阻害剤の医薬組合せ、並びにその使用 |
| WO2024189299A1 (en) * | 2023-03-10 | 2024-09-19 | University Of Southampton | Inhibitors for treating solid tumours |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2998281C (en) | 2008-09-26 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1 antobodies and uses therefor |
| EP4331604B9 (en) | 2008-12-09 | 2025-07-23 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| CA2778714C (en) | 2009-11-24 | 2018-02-27 | Medimmune Limited | Targeted binding agents against b7-h1 |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| BR112013014076A2 (pt) * | 2010-12-06 | 2016-11-22 | Cure Cancer Worldwide Corp | métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer |
| KR20190133790A (ko) | 2011-08-01 | 2019-12-03 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법 |
| ES2808152T3 (es) | 2011-11-28 | 2021-02-25 | Merck Patent Gmbh | Anticuerpos anti-PD-L1 y usos de los mismos |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| HUE054873T2 (hu) | 2014-02-10 | 2021-10-28 | Merck Patent Gmbh | Célzott TGF-béta-gátlás |
| DK3560924T3 (da) | 2015-04-02 | 2021-06-28 | Merck Patent Gmbh | Imidazolonylquinoliner og deres anvendelse som atm-kinase-inhibitorer |
| EP3349731B1 (en) * | 2015-09-16 | 2023-11-01 | Board of Regents, The University of Texas System | Combination of topoisomerase-i inhibitors with immunotherapy in the treatment of cancer |
| AU2017237394A1 (en) * | 2016-03-21 | 2018-11-01 | Astrazeneca Ab | Cinnolin-4-amine compounds and their use in treating cancer |
| IL272352B2 (en) * | 2017-08-11 | 2023-10-01 | Merck Patent Gmbh | Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl]-benzonitrile |
-
2019
- 2019-03-13 MX MX2020009478A patent/MX2020009478A/es unknown
- 2019-03-13 RU RU2020133020A patent/RU2020133020A/ru unknown
- 2019-03-13 JP JP2020547353A patent/JP2021517145A/ja active Pending
- 2019-03-13 EP EP19712706.1A patent/EP3765019A1/en not_active Withdrawn
- 2019-03-13 US US16/980,058 patent/US20210353614A1/en not_active Abandoned
- 2019-03-13 CN CN201980018987.0A patent/CN111867589A/zh active Pending
- 2019-03-13 WO PCT/EP2019/056287 patent/WO2019175243A1/en not_active Ceased
- 2019-03-13 CA CA3093499A patent/CA3093499A1/en active Pending
- 2019-03-13 AU AU2019233596A patent/AU2019233596A1/en not_active Abandoned
- 2019-03-13 KR KR1020207028629A patent/KR20200131270A/ko not_active Withdrawn
-
2020
- 2020-09-06 IL IL277158A patent/IL277158A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3093499A1 (en) | 2019-09-19 |
| US20210353614A1 (en) | 2021-11-18 |
| KR20200131270A (ko) | 2020-11-23 |
| JP2021517145A (ja) | 2021-07-15 |
| EP3765019A1 (en) | 2021-01-20 |
| IL277158A (en) | 2020-10-29 |
| AU2019233596A1 (en) | 2020-10-08 |
| WO2019175243A1 (en) | 2019-09-19 |
| RU2020133020A (ru) | 2022-04-14 |
| CN111867589A (zh) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| MX2021005398A (es) | Terapia del cancer con celulas inmunitarias anti-cd33. | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| MX2019011061A (es) | Compuestos útiles en el tratamiento o prevención de un trastorno mediado por la proteína arginina metil-transferasa 5 (prmt5). | |
| NZ741936A (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| MY198289A (en) | Pharmaceutical Composition for use in a Method of Removing Immune Suppression in a Tumor Microenvironment or Stimulating an Immune System Against Cancer Cells | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| MX2022003063A (es) | Composiciones terapeuticas, combinaciones y metodos de uso. | |
| ZA202405748B (en) | Universal abt compounds and uses thereof | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| WO2017059319A3 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
| MY182232A (en) | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations | |
| WO2018094190A3 (en) | Gut microbiota and treatment of cancer | |
| AU2018278311A1 (en) | IRE1 small molecule inhibitors | |
| MX2017004691A (es) | Bloqueo de cd73. | |
| MY192703A (en) | Compositions containing tucaresol or its analogs | |
| NZ756730A (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| MX2023011105A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
| NZ712691A (en) | C. novyi for the treatment of solid tumors in humans |